These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16883086)

  • 41. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
    Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders.
    Shahim P; Blennow K; Johansson P; Svensson J; Lista S; Hampel H; Andersson LC; Zetterberg H
    Neuromolecular Med; 2017 Mar; 19(1):154-160. PubMed ID: 27646979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperconnectivity of Self-Referential Network as a Predictive Biomarker of the Progression of Alzheimer's Disease.
    Yao W; Chen H; Luo C; Sheng X; Zhao H; Xu Y; Bai F;
    J Alzheimers Dis; 2021; 80(2):577-590. PubMed ID: 33579849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer's Disease.
    Shimizu S; Takenoshita N; Inagawa Y; Tsugawa A; Hirose D; Kaneko Y; Ogawa Y; Serisawa S; Sakurai S; Hirao K; Kanetaka H; Kanbayashi T; Imanishi A; Sakurai H; Hanyu H
    J Alzheimers Dis; 2020; 73(1):117-123. PubMed ID: 31744010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent Alzheimer's pathology in patients with clinical normal pressure hydrocephalus: correlation of high-volume lumbar puncture results, cortical brain biopsies, and outcomes.
    Pomeraniec IJ; Bond AE; Lopes MB; Jane JA
    J Neurosurg; 2016 Feb; 124(2):382-8. PubMed ID: 26339853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.
    Kehoe PG; Al Mulhim N; Zetterberg H; Blennow K; Miners JS
    J Alzheimers Dis; 2019; 72(2):525-535. PubMed ID: 31594235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease.
    Lin YT; Cheng JT; Yao YC; Juo ; Lo YK; Lin CH; Ger LP; Lu PJ
    J Alzheimers Dis; 2009; 18(4):907-18. PubMed ID: 19749420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nerve growth factor expression in astrocytoma and cerebrospinal fluid: a new biomarker for prognosis of astrocytoma.
    Li QY; Yang Y; Zhang Y; Zhang ZJ; Gong AH; Yuan ZC; Lu PS; Zhan LP; Wang P; Feng Y; Xu WL
    Chin Med J (Engl); 2011 Jul; 124(14):2222-7. PubMed ID: 21933631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
    Yin GN; Lee HW; Cho JY; Suk K
    Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.